LXRX

Lexicon Pharmaceuticals, Inc.

1.78

USD

+0.17

+10.56%

Nov 06, 15:59 UTC -5

Closed

After-Market

1.79

+0.01

+0.56%

Lexicon Pharmaceuticals, Inc. (LXRX) Profile

Lexicon Pharmaceuticals, Inc. Profile

About

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomictechnologies to accelerate large-scale analysis of mammalian gene function for drug discovery.

Info & Links

CEO

Michael S. Exton

Headquarters

2445 TECHNOLOGY FOREST BLVD. 11TH FLOOR
THE WOODLANDS, TX 77381, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

275

Employees

Lexicon Pharmaceuticals, Inc. Statistics

Valuation Measures

Market Capitalization²

796.47M

Enterprise Value

804.28M

Enterprise Value/EBITDA(ttm)

-14.83

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

15.45

Price to Book(mrq)

3.67

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

97.53%

Operating Margin(ttm)

-136.89%

Profit Margin(ttm)

-1242.36%

Return on Equity(ttm)

-37.53%

Return on Invested Capital(ttm)

-31.60%

Return on Assets(ttm)

-24.96%

Income Statement

Revenue(ttm)

38.54M

Revenue Per Share(ttm)

0.09

Gross Profit(ttm)

38.11M

EBITDA(ttm)³

-54.22M

Net Income Available to Common(ttm)

-62.35M

Diluted EPS(ttm)

-0.14

Share Statistics

Beta (5Y Monthly)

1.10

52-Week Change

24.48%

S&P 500 52-Week Change

14.03%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

445.23M

Dividend Yield

0.00%

Float⁴

382.66M

% Held by Insiders

14.00%

% Held by Institutions

74.70%

Balance Sheet

Total Cash(mrq)

183.20M

Total Cash Per Share(mrq)

0.41

Total Debt(mrq)

51.89M

Total Debt/Equity(mrq)

29.47%

Current Ratio(mrq)

13.37%

Quick Ratio(mrq)

13.29%

Book Value Per Share(mrq)

0.39

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.05

Free Cash Flow(ytd)

-23.92M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.